allergy to contrast dye], a magnetic resonance imaging [MRI] should be performed.) . CT with FDG-PET scan may be done (optional). • Clinical assessment of tumor status using modified RECIST for assessment of response in MPM4 and irRC47. The investigator may use clinical judgment when determining the clinical significance of laboratory parameter findings throughout the study. The medical monitor may, depending on study criteria, be consulted before enrollment about a potential subject with abnormal laboratory values that are not considered clinically significant. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 38 5.2.2 Treatment Period 5.2.2.1 CRS -207 Prime Vaccinations (PV1, PV2) (with or without low -dose Cy) All subjects will be administered CRS -207 during Weeks 1 and 3 (Day 1 fo r Cohort 1 and Day 2 for Cohort 2) . Cohort 2 only will receive a low -dose Cy administration one day prior to each CRS -207 prime vaccination by i.v. infusion at the dose of 200 mg/m2 in 100 mL normal saline over 30 minutes. CRS -207 will be administered by i.v. infusion at 1 × 109 CFU in 100 mL 0.9% sodium chloride over approximately 1 hour. Prior to CRS -207 administration, subjects will be premedicated with 650 mg of acetaminophen before drug administration. Subjects will receive a minimum of 500 mL of normal saline immediately before CRS -207 infusion and at least 500 mL after infusion (1 L is recommended for subjects who can tolerate it, to mitigate infusion reactions) . Additional fluids may be given for persistent tachycardia, fever or hypotension based on investigator’s discretion. Investigators will not make dose adjustments or changes to administration schedule or rate without p rior approval from sponsor. CRS -207 must not be administered via central venous catheter or infusion port. Vital signs (BP, pulse, respiratory rate, temperature) will be obtained every 30 minutes during the CRS -207 infusion and every hour during post infusion follow - up. Subjects will be observed for at least 4 hours after each infusion. Subjects who are not stable enough to be released at 4 hours after infusion should continue to be monitored until stable. Presence of fever alone does not indicate subject is not clinically stable. Because results for clinical hematology and serum chemistry need to be obtained before each CRS -207 administration, subjects may have blood drawn for these evaluations up to 3 days prior to receiving CRS -207 in Cohort 1 or 2 days prior to Cy for subjects in Cohort 2. Blood samples must not be collected from a central line after infusion of CRS-207 for at least 4 days. Prior to receiving any study drug on Day 1 of Weeks 1 (PV1 for Cohort 1 or XP1 for Cohort 2) and 3 (PV2 for Cohort 1 or XP2 for Cohort 2), the following evaluations will be performed: • Symptom- directed physical examination (May be done up to 3 days prior to CRS -207 dosing ( Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2)). Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 39 • ECOG performance status • Vital signs (BP, pulse, respiratory rate, temperature, pulse oximetry ) and weight taken prior to CRS-207 dosing for on Day 1 for Cohort 1 and prior to Cy dosing on Day 1 and CRS -207 dosing on Day 2 for Cohort 2; blood pressure taken prior to CRS -207 administration (pre -dose) should be taken in supine position after subject has been res ting for at least 5 minutes • Urine or serum pregnancy test (for women of chil dbearing potential only) • Blood draws for c linical hematology, serum chemistry . Blood draw may be done up to 3 days prior to CRS -207 dosing (Cohort 1) or 2 days prior to Cy for sub jects receiving Cy (Cohort 2). • Blood draw (serum and plasma) for tumor m arker(s). Blood draw may be done up to 3 days prior to CRS -207 dosing ( Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2). ( See Section 5.3) • AEs and concomitant medications review • Blood draw for isolation of PBMC (up to 200 mL) . Blood draw may be done up to 3 days prior to CRS -207 dosing ( Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2). ( See Section 5.3) • Blood draw for Lm- and mesothelin -specific immunity assays ( 10 m L). Blood draw may be done up to 3 days prior to CRS -207 dosing ( Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2). ( See Section 5.3) • Blood draw for Class I HLA -typing (A and B, low resolution) ; at Week 1 (PV1) only . Blood draw may be done up to 3 days prior to CRS -207 dosing (Cohort 1) or 2 days prior to Cy for subjects receiving Cy (Cohort 2 ). (see Section 5.3) • Optional core needle biopsy; may be done anytime between screening and prior to dosing at Week 1 (PV1) only (see Section 5.3) Note: Urine pregnancy test and blood draws for hematology, chemistry and tumor markers are not required at Week 1 (PV1) if Screening Visit is conducted within 3 days prior to PV1 Visit. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 40 5.2.2.2 CRS -207 Prime Vaccinati ons Follow- up One day after CRS -207 infusion (Day 2 for Cohort 1 or Day 3 for Cohort 2), the following evaluation s will be performed : • Vital signs (BP, pulse, respiratory rate, temperature , pulse oximetry ) • Blood draws for clinical hematology, serum chemistry . Any unexpected Grade 3 laboratory abnormalities should be repeated within 24-72 hours. • AEs and concomitant medications review • Blood draw for Lm- and mesothelin -specific immunity assays ( 10 m L). Blood should be drawn within 20- 26 hours after st art of CRS -207 dosing. (See Section 5.3) One week (7 ± 1 days) after each CRS -207 infusion, subjects will be contacted by phone to assess AEs and concomitant medications and to confirm initiation of 7- day course of antibiotics ( after 2nd prime vaccination [PV2] only). 5.2.2.3 Chemotherapy Treatment: Pemetrexed and Cisplatin Administration (CY1 to CY6) On Day 1 of Weeks 5 (CY1) , 8 (CY2), 11 (CY3), 14 (CY4), 17 (CY5) and 20 (CY6), pemetrexed and c isplatin treatment will be administered . Pemetrexed will be administered at 500 mg/m2 BSA in 100 mL 0.9% sodium chloride administered over 10 minutes as an intravenous infusion. Cisplatin will be administered at 75 mg/m2 BSA in 1L 0.9% sodium chloride with mannitol 30g/L infused over 2 hours , beginning approximately 30 minutes after the end of pemetrexed administration . Subjects may receive pre- medications (e.g. folic acid, cyanocobalamin , and anti -emetics) and pre- and post -infusion hydration per standard of c are and investigator’s practice. Dose reductions may be required for subject s with hepatic or renal impairment or history of toxicity to pemetrexed or cisplatin. If a subject is determined to be intolerant to cisplatin after at least one dose, carboplatin may be substituted to be administered wi th pemetrexed per standard of care with the approval of the Sponsor. Subjects who complete at least 2 cycles of pemetrexed/cisplatin may go on to receive CRS -207 3 weeks after their final cycle of pemetrexed/cisplatin. Subjects Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 41 who receive less than 2 cycles will be discontinued from treatment and continued to be followed for safety and clinical and immune responses. Prior to pemetrexed/cisplatin treatment, the following procedures will be performed: • Symptom- directed physical examination (May be done up to 3 days prior to dosing) • ECOG performance status • Vital signs (BP, pulse, respiratory rate, temperature, pulse oximetry ) and weight • Blood draws for c linical hematology, serum chemistry . Blood draw may be done up to 3 days prior to dosing. • Blood draw (serum and plasma) for tumor m arker(s). Blood draw may be done up to 3 days prior to dosing. ( See Section 5.3) • AEs and concomitant medications review • Spiral CT scan of thorax and abdomen with optional FDG -PET scan; at Weeks 5 (CY1), 11 (CY3), 17 (CY5). If a subject cannot have a CT scan [e.g. allergy to contrast dye], a n MRI should be performed. CT scan may be done within ±7 days of scheduled timepoint. • Clinical assessment of tumor status using modified RECIST for assessment of response in MPM4 and irRC47; at Weeks 5 (CY1) , 11 (CY3), 17 (CY5) • Pulmonary function tests: VC, FVC and FEV 1; at Weeks 5 (CY1), 11 (CY3), 17 (CY5) for Cohort 2 only • Blood draw for isolation of PBMC (up to 200 mL); at Week 5 (CY1) only. Blood draw may be done up to 3 days prior to dosing. ( See Section 5.3) • Blood draw for Lm- and mesothelin -specific immunity assays ( 10 m L); at Week 5 (CY1) only. Blood draw may be done up to 3 days prior to dosing.